LONDON (Alliance News) - Imperial Innovations Group PLC on Thursday said one of the companies within its portfolio, TopiVert Pharma Ltd, has progressed the study evaluating its rectal formulation of TOP1288 in symptomatic ulcerative colitis patients.
Imperial said Topivert has revealed the first patients have been dosed as part of its phase IIa proof-of-concept study for TOP1288, a potent inhibitor of key kinases involved in inflammation that is being developed to help treat a form of inflammatory bowel disease.
The phase I study was completed in March with healthy volunteers and the clinical data supported the idea that TOP1288 could potentially produce sustained pharmacological effects in mucosal tissues after local administration, but without the undesirable side effects often seen in the target patients using existing treatments.
The phase II study is looking specifically into the efficacy, safety and tolerability of TOP1288. The study will recruit up to 60 patients at sites across eight European countries and is anticipated to report in the second half of 2017, Imperial Innovations said.
TopiVert will also commence a follow-on Phase I study with the oral formulation of TOP1288 in early 2017. This study is also expected to report in the second half of 2017.
By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
